Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM.

Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0472-2. [Epub ahead of print]

PMID:
30967620
2.

Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA.

Menolfi D, Jiang W, Lee BJ, Moiseeva T, Shao Z, Estes V, Frattini MG, Bakkenist CJ, Zha S.

Nat Commun. 2018 Dec 17;9(1):5351. doi: 10.1038/s41467-018-07798-3.

3.

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM.

Cancer Discov. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877. Epub 2018 Oct 24.

4.

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP.

Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23.

5.

Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.

Epstein DJ, Seo SK, Huang YT, Park JH, Klimek VM, Berman E, Tallman MS, Frattini MG, Papanicolaou GA.

J Infect. 2018 Sep;77(3):227-234. doi: 10.1016/j.jinf.2018.03.015. Epub 2018 May 7.

PMID:
29746955
6.

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.

Zeidan AM, Knaus HA, Robinson TM, Towlerton AMH, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD.

Clin Cancer Res. 2018 Aug 1;24(15):3519-3527. doi: 10.1158/1078-0432.CCR-17-3763. Epub 2018 May 1.

7.

Highly Sensitive Virome Capture Sequencing Technique VirCapSeq-VERT Identifies Partial Noncoding Sequences but no Active Viral Infection in Cutaneous T-Cell Lymphoma.

Anderson ME, Nagy-Szakal D, Jain K, Patrone CC, Frattini MG, Lipkin WI, Geskin LJ.

J Invest Dermatol. 2018 Jul;138(7):1671-1673. doi: 10.1016/j.jid.2018.01.024. Epub 2018 Feb 7. No abstract available.

8.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA.

Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.

PMID:
29339097
9.

Geminin inhibits a late step in the formation of human pre-replicative complexes.

Wu M, Lu W, Santos RE, Frattini MG, Kelly TJ.

J Biol Chem. 2014 Oct 31;289(44):30810-21. doi: 10.1074/jbc.M114.552935. Epub 2014 Sep 17.

10.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R.

Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

11.

An arrayed genome-scale lentiviral-enabled short hairpin RNA screen identifies lethal and rescuer gene candidates.

Bhinder B, Antczak C, Ramirez CN, Shum D, Liu-Sullivan N, Radu C, Frattini MG, Djaballah H.

Assay Drug Dev Technol. 2013 Apr;11(3):173-90. doi: 10.1089/adt.2012.475. Epub 2012 Nov 30.

12.

Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A.

Cell. 2012 Oct 12;151(2):344-55. doi: 10.1016/j.cell.2012.08.038.

13.

Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.

Antczak C, Shum D, Bassit B, Frattini MG, Li Y, de Stanchina E, Scheinberg DA, Djaballah H.

Bioorg Med Chem Lett. 2011 Aug 1;21(15):4528-32. doi: 10.1016/j.bmcl.2011.05.129. Epub 2011 Jun 12.

14.

Comparison of luminescence ADP production assay and radiometric scintillation proximity assay for Cdc7 kinase.

Takagi T, Shum D, Parisi M, Santos RE, Radu C, Calder P, Rizvi Z, Frattini MG, Djaballah H.

Comb Chem High Throughput Screen. 2011 Sep;14(8):669-87.

15.

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA.

Blood. 2010 Jul 15;116(2):171-9. doi: 10.1182/blood-2009-10-250993. Epub 2010 Apr 16.

16.

Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors.

Antczak C, Veach DR, Ramirez CN, Minchenko MA, Shum D, Calder PA, Frattini MG, Clarkson B, Djaballah H.

Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. doi: 10.1016/j.bmcl.2009.10.085. Epub 2009 Oct 23.

17.

An exo-cell assay for examining real-time gamma-secretase activity and inhibition.

Shelton CC, Tian Y, Frattini MG, Li YM.

Mol Neurodegener. 2009 Jun 2;4:22. doi: 10.1186/1750-1326-4-22.

18.

Strategy for incorporating molecular and cytogenetic markers into acute myeloid leukemia therapy.

Frattini MG, Maslak PG.

J Natl Compr Canc Netw. 2008 Nov;6(10):995-1002. Review.

PMID:
19176197
19.

Multiple mechanisms contribute to Schizosaccharomyces pombe origin recognition complex-DNA interactions.

Houchens CR, Lu W, Chuang RY, Frattini MG, Fuller A, Simancek P, Kelly TJ.

J Biol Chem. 2008 Oct 31;283(44):30216-24. doi: 10.1074/jbc.M802649200. Epub 2008 Aug 22.

20.

Redundant control of rereplication in fission yeast.

Gopalakrishnan V, Simancek P, Houchens C, Snaith HA, Frattini MG, Sazer S, Kelly TJ.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13114-9. Epub 2001 Oct 23.

23.
24.
25.

The role of the E1 and E2 proteins in the replication of human papillomavirus type 31b.

Frattini MG, Laimins LA.

Virology. 1994 Nov 1;204(2):799-804.

PMID:
7941349
27.

Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation.

Meyers C, Frattini MG, Hudson JB, Laimins LA.

Science. 1992 Aug 14;257(5072):971-3.

PMID:
1323879
28.

In situ enzymology of DNA replication and ultraviolet-induced DNA repair synthesis in permeable human cells.

Dresler SL, Frattini MG, Robinson-Hill RM.

Biochemistry. 1988 Sep 20;27(19):7247-54.

PMID:
3207673

Supplemental Content

Loading ...
Support Center